$BCR (CR Bard Inc.)

$BCR {{ '2017-08-09T13:54:30+0000' | timeago}} • Announcement

$BCR and $BDX have announced that they have received the approval of $BCR’s shareholders for the proposed acquisition of $BCR by $BDX in a stock and cash transaction. The proposed transaction remains subject to other conditions and approvals, and is presently expected to close in the fourth calendar quarter of 2017.

$MMSI {{ '2017-11-16T17:40:51+0000' | timeago}} • Announcement

$MMSI signed purchase agreement with $BDX for divestment assets in connection with its proposed acquisition of $BCR$MMSI expects the acquisition to provide incremental annual revenues of $42-48MM, and adjusted gross margins for the subject product lines of 60-70%. $MMSI expects deal to provide $0.10-0.19 in adjusted EPS accretion in FY18.

$MMSI {{ '2017-11-16T17:37:46+0000' | timeago}} • Announcement

$MMSI signed an asset purchase agreement with $BDX to buy certain assets which $BDX proposes to sell in connection with its proposed acquisition of $BCR. $MMSI proposes to buy the Aspira Pleural Effusion Drainage Kits and the Aspira Peritoneal Drainage System currently marketed by $BCR. The purchase price is $100MM.

$BCR {{ '2017-10-11T21:37:38+0000' | timeago}} • Announcement

$BCR declared a regular quarterly dividend of $0.26 per share on its common stock. In connection with the pending merger with Becton, Dickinson & Company, the quarterly dividend will be payable on December 29, 2017 to shareholders of record on December 8, 2017.

$BCR {{ '2017-08-09T13:54:30+0000' | timeago}} • Announcement

$BCR and $BDX have announced that they have received the approval of $BCR’s shareholders for the proposed acquisition of $BCR by $BDX in a stock and cash transaction. The proposed transaction remains subject to other conditions and approvals, and is presently expected to close in the fourth calendar quarter of 2017.

$GS {{ '2017-07-19T11:22:37+0000' | timeago}} • Webcast

$GS advised a number of important transactions that were announced during 2Q17, including $BCR's $24Bil sale to $BDX. $AMZN's $13.7Bil acquisition of $WFM, and $DFT's $7.6Bil merger with $DLR.

$BCR {{ '2017-06-14T21:19:50+0000' | timeago}} • Announcement

$BCR declared a regular quarterly dividend of $0.26 per share. The current indicated annual dividend rate is $1.04 per share. The dividend is payable on August 4, 2017 to shareholders of record at the close of business on July 24, 2017.

$BDX {{ '2017-06-12T07:19:32+0000' | timeago}} • Announcement

$BDX and $BCR received a request for additional information from the Federal Trade Commission in connection with BD's pending acquisition of C.R. Bard. In April 2017, BD agreed to buy Bard in a $24Bil transaction. Both companies expect to get regulatory approvals and close the transaction in the fall of 2017.

$BDX {{ '2017-04-24T15:32:49+0000' | timeago}} • Announcement

$BDX appointed Tom Polen as president of $BDX, effective immediately. In his new role, Mr. Polen will oversee all of BD's operating segments, the Medical and Life Sciences segments, as well as the new Interventional segment, which will include the $BCR businesses following the close of $BDX's acquisition of $BCR.

$BDX {{ '2017-04-24T15:00:46+0000' | timeago}} • Announcement

$BDX agreed to buy $BCR. About $300MM of annual, pre-tax, run-rate cost synergies are expected by FY20. $BDX also expects to benefit from revenue synergies beginning in FY19. This is expected to improve $BDX's gross margins by about 300 basis points in FY18, increase $BDX's EPS growth trajectory to the mid-teens, and generate strong cash flow.

$BDX {{ '2017-04-24T14:58:54+0000' | timeago}} • Announcement

$BDX agreed to buy $BCR$BCR common shareholders will be entitled to receive about $222.93 in cash and 0.5077 shares of $BDX stock per $BCR share, or a total of value of $317.00 per $BCR common share. This will be immediately accretive and is expected to generate high-single digit accretion to adjusted EPS in FY19.

$BDX {{ '2017-04-24T14:57:11+0000' | timeago}} • Announcement

$BDX agreed to buy $BCR for $317 per share in cash and stock, for a total consideration of $24Bil. The agreement has been unanimously approved by BoDs of both companies. The transaction is expected to close in the fall of 2017. At closing, $BCR shareholders will own about 15% of the combined company.

$BCR {{ '2017-04-19T21:01:31+0000' | timeago}} • Announcement

$BCR declared a regular quarterly dividend of $0.26 per share on its common stock. The current indicated annual dividend rate is $1.04 per share. The dividend is payable on May 12, 2017 to shareholders of record on May 1, 2017.

$BCR {{ '2017-01-26T22:35:42+0000' | timeago}} • Announcement

$BCR expects 2017 net sales growth of 4-5% on an as-reported basis. Excluding the impact of foreign exchange, net sales are predicted to increase 6-6.5% over 2016. EPS, after adjusting for amortization of intangibles and certain items, are expected to be $11.45-11.75, representing 11-14% growth over 2016.

$BCR {{ '2017-01-26T22:33:39+0000' | timeago}} • Announcement

$BCR reported a rise in 4Q16 earnings driven by higher sales from its four businesses. Net income rose to $159.6MM or $2.11 per share from $136.3MM or $1.79 per share last year. Sales grew to $967.1MM from $870.8MM. Adjusted EPS increased to $2.77 from $2.43.

$BCR {{ '2016-12-14T22:56:07+0000' | timeago}} • Announcement

The BoD of $BCR declared a regular quarterly dividend of $0.26 per share on its common stock. The current indicated annual dividend rate is $1.04 per share. The dividend is payable on Feb. 3, 2017 to shareholders of record at the close of business on Jan. 23, 2017.

$BCR {{ '2016-10-26T10:54:02+0000' | timeago}} • Webcast

Medical device maker $BCR said, in its BioSurgery division, the company is preparing for the launch of its Tridyne aortic sealant and expects to launch the product in 1Q17. It also plans to launch its Progel Emerald lung sealant -- designed to improve visibility during minimally invasive and robotic thoracic surgery -- in 2Q17.

$BCR {{ '2016-10-25T21:01:15+0000' | timeago}} • Announcement

$BCR raised its 2016 net sales growth outlook as-reported basis to 8-9% from prior range of 7-8% and its sales, excluding impact of FX, forecast to 9-10% from prior range of 8-9%. $BCR lifted adjusted EPS projection to $10.23-10.28 from prior estimate of $10.10-10.20. The revised EPS forecast represents 13% YoverY growth.

$BCR {{ '2016-10-25T20:57:54+0000' | timeago}} • Announcement

Medical device manufacturer $BCR swung to a 3Q16 profit from a loss last year, driven by lower costs and expenses as well as higher revenues. Net income was $96.4MM or $1.27 per share compared to a loss of $86MM or $1.16 per share last year. Net sales grew to $941.9MM from $865.7MM. Adjusted EPS increased to $2.64 from $2.28.

$BCR {{ '2016-10-12T21:22:49+0000' | timeago}} • Announcement

$BCR's BoD declared a regular quarterly dividend of $0.26 per share on its common stock, payable on Nov. 4, 2016 to shareholders of record at the close of business on Oct. 24, 2016.

$BCR {{ '2016-09-20T08:01:15+0000' | timeago}} • Announcement

Medical company $BCR said the US FDA has approved an Investigational Device Exemption (IDE) application to modify primary endpoint to a 6-month time point for Lutonix 014 Drug Coated Balloon (DCB) Catheter. The Lutonix 014 DCB has been available commercially in Europe since 2013 and is available in most geographies outside the US.

Recent Transcripts

INFU (InfuSystem Holdings, Inc.)
Friday, November 10 2017 - 4:00pm
ICUI (ICU Medical, Inc.)
Thursday, November 9 2017 - 9:30pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
ICAD (iCAD, Inc.)
Wednesday, November 8 2017 - 9:30pm
LXRX (Lexicon Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 3:00pm
ITCI (Intra-Cellular Therapies, Inc.)
Wednesday, November 8 2017 - 1:30pm
JAZZ (Jazz Pharmaceuticals Public Limited Company)
Tuesday, November 7 2017 - 9:30pm
KERX (Keryx Biopharmaceuticals Inc.)
Monday, November 6 2017 - 10:00pm
XRAY (DENTSPLY International Inc.)
Friday, November 3 2017 - 12:30pm
IRIX (IRIDEX Corporation)
Thursday, November 2 2017 - 9:00pm
PODD (Insulet Corporation)
Thursday, November 2 2017 - 8:30pm
LIVN (LivaNova PLC)
Thursday, November 2 2017 - 1:00pm
KPTI (Karyopharm Therapeutics, Inc.)
Thursday, November 2 2017 - 12:30pm
IRWD (Ironwood Pharmaceuticals, Inc.)
Thursday, November 2 2017 - 12:30pm
KTWO (K2M Group Holdings, Inc.)
Wednesday, November 1 2017 - 9:00pm
ICPT (Intercept Pharmaceuticals, Inc.)
Wednesday, November 1 2017 - 12:30pm
IDXX (IDEXX Laboratories, Inc.)
Tuesday, October 31 2017 - 12:30pm
CRY (CryoLife Inc.)
Tuesday, October 31 2017 - 12:00pm
CYTK (Cytokinetics, Incorporated)
Thursday, October 26 2017 - 8:30pm
IART (Integra LifeSciences Holdings Corporation)
Thursday, October 26 2017 - 12:30pm

AlphaGraphics you may like